Elmex Drugs & Healthcare Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 07-12-2024
- Paid Up Capital ₹ 0.20 M
as on 07-12-2024
- Company Age 16 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue 28.94%
(FY 2020)
- Profit -17.63%
(FY 2020)
- Ebitda 112.22%
(FY 2020)
- Net Worth 29.87%
(FY 2020)
- Total Assets 18.82%
(FY 2020)
About Elmex Drugs & Healthcare
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Aniraj Krishnannair, Girija Panicker, and Babu Sebastian serve as directors at the Company.
- CIN/LLPIN
U52310KL2008PTC023412
- Company No.
023412
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Nov 2008
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Pathanamthitta, Kerala, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Elmex Drugs & Healthcare Private Limited offer?
Elmex Drugs & Healthcare Private Limited offers a wide range of products and services, including .
Who are the key members and board of directors at Elmex Drugs & Healthcare?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aniraj Krishnannair  | Managing Director | 17-Nov-2008 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Girija Panicker | Director | 17-Nov-2008 | Current |
| Babu Sebastian | Director | 30-Sep-2014 | Current |
Financial Performance of Elmex Drugs & Healthcare.
Elmex Drugs & Healthcare Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 28.94% increase. The company also saw a substantial fall in profitability, with a 17.63% decrease in profit. The company's net worth Soared by an impressive increase of 29.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Elmex Drugs & Healthcare?
In 2019, Elmex Drugs & Healthcare had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Elmex Drugs & Healthcare?
Unlock and access historical data on people associated with Elmex Drugs & Healthcare, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Elmex Drugs & Healthcare, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Elmex Drugs & Healthcare's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
